Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL CR vs BRISDELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder (off-label),Hot flashes (off-label)
FDA-approved: Treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause.,Off-label: Management of depression, anxiety disorders, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder.
12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.
8 mg orally once daily, taken at bedtime.
The terminal elimination half-life of paroxetine (PAXIL CR) is approximately 15-20 hours. This supports once-daily dosing and requires about 5-7 days to reach steady-state concentration.
Terminal elimination half-life is approximately 9-11 hours for paroxetine (the active ingredient in Brisdelle). This supports once-daily dosing; steady-state is achieved within 7-14 days.
Extensively metabolized in the liver primarily via cytochrome P450 enzyme CYP2D6. Paroxetine is a potent inhibitor of CYP2D6. Metabolites are less active and are excreted in urine and feces.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6. Metabolites are glucuronidated and excreted renally.
Renal excretion accounts for approximately 64% of the administered dose, with 2% as unchanged parent drug and the remainder as metabolites. Fecal excretion accounts for about 36%, mostly as metabolites. Less than 1% is excreted in bile.
Primarily renal excretion as metabolites; approximately 60% of a radiolabeled dose is recovered in urine and 30% in feces over 10 days. Less than 1% excreted unchanged.
Approximately 93-95% bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin.
Approximately 95% bound to plasma proteins, primarily to albumin and alpha-1 acid glycoprotein.
Apparent volume of distribution (Vd/F) is approximately 3-28 L/kg, with an average of about 13 L/kg. This wide distribution indicates extensive tissue partitioning, with brain concentrations several times higher than plasma.
Volume of distribution is about 3-28 L/kg (mean ~13 L/kg), indicating extensive tissue distribution.
Oral bioavailability of PAXIL CR is about 30% due to first-pass metabolism, but is lower than the immediate-release formulation (50%). Food does not significantly affect bioavailability.
Oral bioavailability is approximately 50-100% due to extensive first-pass metabolism; absolute bioavailability is about 50% for the immediate-release formulation.
Creatinine clearance 30-60 m L/min: use lower end of dosing range (12.5 mg/day maximum). Creatinine clearance <30 m L/min: not recommended.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥ 30 m L/min). For severe renal impairment (Cr Cl < 30 m L/min) or end-stage renal disease, not recommended due to lack of data.
Child-Pugh Class A or B: initial dose 12.5 mg/day, maximum 25 mg/day. Child-Pugh Class C: not recommended.
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate hepatic impairment (Child-Pugh B): maximum dose 4 mg orally once daily. Severe hepatic impairment (Child-Pugh C): contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for use in pediatric patients; safety and efficacy not established.
Initial dose 12.5 mg/day; maximum 25 mg/day. Increased sensitivity to serotonin reuptake inhibition; monitor for hyponatremia and QT prolongation.
For patients >65 years, start with 4 mg orally once daily at bedtime; may increase to 8 mg once daily based on response and tolerability. Monitor closely for sedation and falls.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term trials. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Bleeding abnormalities,Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Hyponatremia,Bone fractures,Discontinuation syndrome (withdrawal reactions)
Suicidality risk in young adults,Serotonin syndrome with concurrent serotonergic drugs,Bone fractures risk,Sexual dysfunction,Abnormal bleeding risk,Angle-closure glaucoma risk,Hyponatremia in elderly or volume-depleted patients,Discontinuation syndrome upon abrupt withdrawal,Pregnancy: Potential harm to neonates (persistent pulmonary hypertension, serotonin syndrome),Lactation: Excreted in breast milk
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concomitant use with pimozide or thioridazine,Known hypersensitivity to paroxetine or any component of the formulation
Concomitant use with MAOIs (or within 14 days of MAOI discontinuation),Concomitant use with thioridazine,Concomitant use with pimozide,Hypersensitivity to paroxetine or any component,Pregnancy (especially third trimester) due to risk of neonatal complications
No specific food restrictions, but avoid excessive alcohol intake. Grapefruit has not been reported to interact significantly with paroxetine.
Avoid alcohol due to additive central nervous system depression. No specific food interactions; take without regard to meals.
First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) and prolonged QT interval. Late third trimester exposure may cause serotonin syndrome in neonate.
Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses greater than human therapeutic doses. In humans, retrospective studies suggest a small increased risk of congenital heart defects (primarily ventricular septal defects) with first-trimester exposure. Third-trimester exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and neonatal withdrawal syndrome (respiratory distress, feeding difficulties, jitteriness).
Paroxetine is excreted into breast milk. M/P ratio is approximately 0.39. Milk levels vary; peak concentration occurs 2-4 hours post-dose. Most studies show no adverse effects in breastfed infants, but cases of irritability, poor feeding, and transient serotonin-like symptoms have been reported. Use caution; monitor infant for drowsiness, restlessness, and weight gain.
Paroxetine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.7. Estimated infant dose is 1-2% of maternal weight-adjusted dose. No adverse effects have been consistently reported in breastfed infants, but caution is advised due to potential for serotonin-related effects. Benefits versus risks should be assessed.
Paroxetine clearance may decrease in pregnancy, leading to higher plasma concentrations. However, dose adjustments are generally not routinely recommended due to limited data. Consider therapeutic drug monitoring if response is inadequate or side effects occur. The risk of birth defects with high doses (>30 mg/day) may be increased, so use lowest effective dose (12.5-37.5 mg/day CR). Avoid abrupt discontinuation; taper slowly postpartum.
No specific dose adjustment is recommended solely due to pregnancy; however, pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) may lead to decreased drug levels. Clinical monitoring and dose titration based on therapeutic response and tolerability are advised. Avoid abrupt discontinuation to prevent withdrawal effects.
PAXIL CR (paroxetine extended-release) has a longer half-life than immediate-release, allowing once-daily dosing but requiring 3-4 weeks for steady state. Due to its potent CYP2D6 inhibition, use caution with tamoxifen (reduces active metabolite) and with other serotonergic drugs (risk of serotonin syndrome). Discontinuation syndrome is common; taper gradually. Pregnancy category D; avoid in third trimester due to risk of persistent pulmonary hypertension of the newborn (PPHN).
BRISDELLE (paroxetine mesylate) is a selective serotonin reuptake inhibitor (SSRI) indicated for vasomotor symptoms (VMS) in menopause. It is the only non-hormonal therapy FDA-approved for moderate to severe VMS. Dosing starts at 7.5 mg once daily, typically at bedtime to minimize daytime sedation. Avoid concurrent use with MAOIs, other SSRIs/SNRIs, or strong CYP2D6 inhibitors (e.g., paroxetine itself). Monitor for serotonin syndrome, especially with triptans or linezolid. Discontinue gradually to avoid withdrawal symptoms. Note that paroxetine is pregnancy category D; use effective contraception.
Take this medication once daily, usually in the morning with or without food. Swallow the tablet whole; do not crush, chew, or divide.,It may take several weeks to feel the full benefit; do not stop suddenly as withdrawal symptoms may occur.,Avoid alcohol while taking PAXIL CR as it can increase dizziness and drowsiness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any suicidal thoughts or unusual changes in mood immediately.,Do not take with MAO inhibitors (e.g., phenelzine) or within 14 days of stopping them.,Contact a healthcare professional if you experience symptoms of serotonin syndrome (fever, muscle stiffness, confusion, rapid heart rate).
Take BRISDELLE at bedtime to reduce daytime drowsiness.,Do not crush or chew the capsule; swallow whole.,It may take 2–4 weeks to see full benefit for hot flashes.,Avoid alcohol as it can increase sedation.,Do not stop suddenly; taper under medical guidance.,Report any suicidal thoughts, worsening depression, or unusual behavior changes.,Contact doctor if you experience severe headache, nausea, or rapid heartbeat (serotonin syndrome).,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL CR vs BRISDELLE, answered by our medical review team.
PAXIL CR is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. BRISDELLE is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); paroxetine is the active ingredient. Enhances serotonergic activity by blocking serotonin reuptake into presynaptic neurons, augmenting serotonin levels in the synaptic cleft.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL CR and BRISDELLE depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL CR is: 12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.. The standard adult dose of BRISDELLE is: 8 mg orally once daily, taken at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL CR and BRISDELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL CR is classified as Category C. First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: . BRISDELLE is classified as Category C. Pregnancy Category C. In animal studies, paroxetine (active ingredient of Brisdelle) has been associated with increased fetal malformations (including cardiovascular) at doses grea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.